Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Int Cancer Conf J ; 13(2): 153-157, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38524659

RESUMO

Hepatic arterial infusion chemotherapy (HAIC) for liver metastases (LMs) from breast cancer is not a standard of care, but its effectiveness in patients with extensive LMs who cannot tolerate systemic therapy has been reported. Herein, we report a case of breast cancer LMs that were controlled by anthracycline-based HAIC. A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38 months; letrozole, nivolumab/fulvestrant, eribulin, gemcitabine/vinorelbine, high-dose toremifene/abemaciclib, and capecitabine for 21 months in total). However, owing to its adverse effects and the continued progression of the LMs, systemic therapy was switched to HAIC (40 mg/body epirubicin on day 1, 4 mg/body mitomycin C on days 1 and 15, and 500 mg/body 5-fluorouracil on days 1, 8, and 15; 28-day courses). In response to HAIC, the LMs remarkably regressed and were controlled for 17 months without severe adverse effects. HAIC was stopped when multiple brain metastases arose, and the patient died 2 months later. This case suggests that HAIC is a reasonable option for patients with extensive LMs, even in the late stage of treatment. HAIC recipients should be carefully selected through multidisciplinary discussions as the survival benefits of HAIC over systemic treatment remain unclear. Our findings identify a potential window for the use of traditional chemotherapeutic agents such as anthracyclines. Novel strategies to improve drug delivery are warranted in the future.

2.
Cancer Sci ; 112(8): 3338-3348, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-34036661

RESUMO

Predicting pathogenic germline variants (PGVs) in breast cancer patients is important for selecting optimal therapeutics and implementing risk reduction strategies. However, PGV risk factors and the performance of prediction methods in the Japanese population remain unclear. We investigated clinicopathological risk factors using the Tyrer-Cuzick (TC) breast cancer risk evaluation tool to predict BRCA PGVs in unselected Japanese breast cancer patients (n = 1,995). Eleven breast cancer susceptibility genes were analyzed using target-capture sequencing in a previous study; the PGV prevalence in BRCA1, BRCA2, and PALB2 was 0.75%, 3.1%, and 0.45%, respectively. Significant associations were found between the presence of BRCA PGVs and early disease onset, number of familial cancer cases (up to third-degree relatives), triple-negative breast cancer patients under the age of 60, and ovarian cancer history (all P < .0001). In total, 816 patients (40.9%) satisfied the National Comprehensive Cancer Network (NCCN) guidelines for recommending multigene testing. The sensitivity and specificity of the NCCN criteria for discriminating PGV carriers from noncarriers were 71.3% and 60.7%, respectively. The TC model showed good discrimination for predicting BRCA PGVs (area under the curve, 0.75; 95% confidence interval, 0.69-0.81). Furthermore, use of the TC model with an optimized cutoff of TC score ≥0.16% in addition to the NCCN guidelines improved the predictive efficiency for high-risk groups (sensitivity, 77.2%; specificity, 54.8%; about 11 genes). Given the influence of ethnic differences on prediction, we consider that further studies are warranted to elucidate the role of environmental and genetic factors for realizing precise prediction.


Assuntos
Proteína BRCA1/genética , Proteína BRCA2/genética , Neoplasias da Mama/genética , Proteína do Grupo de Complementação N da Anemia de Fanconi/genética , Triagem de Portadores Genéticos/métodos , Mutação em Linhagem Germinativa , Neoplasias Ovarianas/genética , Adulto , Idade de Início , Idoso , Idoso de 80 Anos ou mais , Feminino , Predisposição Genética para Doença , Humanos , Japão , Pessoa de Meia-Idade , Taxa de Mutação , Linhagem , Vigilância da População , Medição de Risco
3.
Surg Case Rep ; 5(1): 190, 2019 Dec 05.
Artigo em Inglês | MEDLINE | ID: mdl-31808013

RESUMO

BACKGROUND: Meckel's diverticulum is considered the most prevalent congenital anomaly of the gastrointestinal tract. Approximately 4% of patients are symptomatic with complications such as bleeding, intestinal obstruction, and inflammation, while axial torsion of Meckel's diverticulum is rare, particularly in pregnancy. CASE PRESENTATION: A 31-year-old woman in week 15 of pregnancy complained of epigastric pain, nausea and vomiting. Clinical diagnosis was severe hyperemesis gravidarum. Because the symptoms persisted during hospitalization, CT was performed and revealed dilated small bowel loops with multiple air-fluid levels. In the right mid-abdomen, there was a large part of air containing a cavity connected to the small intestine, which was considered a dilated bowel loop. Emergency laparotomy was performed and axial torsion of a large Meckel's diverticulum measuring 11 cm was found at a few centimeters proximal to the ileocecal valve. Ileocecal resection including Meckel's diverticulum was performed. The postoperative course was uneventful. At 40 weeks gestation, she had vaginal delivery of normal baby. CONCLUSION: The physiological and anatomical changes in pregnancy can make a straightforward clinical diagnosis difficult. Prompt diagnosis and management were needed in order to avoid significant maternal and fetal risks. The use of imaging examinations, especially CT examination, with proper timing may be helpful to prevent delay in diagnosis and surgical intervention. Here, we report the case of a patient with axial torsion of Meckel's diverticulum in pregnancy. To our knowledge, axial torsion of Meckel's diverticulum in the first trimester of pregnancy has not been reported in the English medical literature.

4.
Surg Today ; 41(9): 1219-23, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21874418

RESUMO

PURPOSE: It has been reported that complete cytoreduction using peritonectomy combined with intraperitoneal chemotherapy improves the prognosis of patients with pseudomyxoma peritonei (PMP); however, this treatment strategy remains controversial, especially at nonspecialized institutes, because of its high morbidity rate. METHODS: We reviewed the clinical records of 15 consecutive patients with PMP, treated in nonspecialized hospitals and observed by one of us between 1999 and 2010. Cytoreductive surgery was done using peritonectomy procedures with intraperitoneal chemotherapy and was performed with curative intent, |in accordance with Sugarbaker. RESULTS: All patients had mucinous tumors disseminated in the peritoneal cavity. Complete cytoreduction was achieved in 12 patients. Morbidity was 40% (6/15) and mortality was 0% (0/15). After a median follow-up period of 43 months, the 12 patients who underwent complete cytoreduction were disease-free with good quality of life, and 1 of the 3 patients who underwent incomplete cytoreduction was alive with disease. CONCLUSIONS: These findings suggest that peritonectomy with intraperitoneal chemotherapy for PMP can provide prognostic benefit, even at nonspecialized hospitals. Considering the treatment risk, it should ideally be performed at a referral center, or at least by an experienced surgeon.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Cisplatino/administração & dosagem , Criocirurgia , Mitomicina/administração & dosagem , Neoplasias Peritoneais/cirurgia , Pseudomixoma Peritoneal/cirurgia , Idoso , Idoso de 80 Anos ou mais , Terapia Combinada , Feminino , Hospitais , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Peritoneais/tratamento farmacológico , Neoplasias Peritoneais/mortalidade , Complicações Pós-Operatórias/epidemiologia , Pseudomixoma Peritoneal/tratamento farmacológico , Pseudomixoma Peritoneal/mortalidade , Estudos Retrospectivos , Análise de Sobrevida , Taxa de Sobrevida , Resultado do Tratamento
5.
Surg Today ; 41(8): 1037-40, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21773890

RESUMO

PURPOSE: Surgical site infections (SSI) in an abdominoperineal resection (APR) occur more frequently than in other types of operations for patients with colorectal cancer. Perineal wounds are the most vulnerable sites, and they may be caused by stool contamination. Indocyanine green (ICG) fluorescence imaging, by which sensitive detection was possible, was used as a marker of perineal wound contamination. METHOD: Indocyanine green was transanally injected to the rectum before operation, and fluorescence images were obtained during the operation in three patients who underwent APR. RESULTS: One subject, in whom gross contamination was not visible, had an SSI, and a trace of ICG fluorescence was detectable in the perianal skin. The other two subjects, in whom skin preparation was completely performed until ICG contamination was eliminated, were free from SSI. CONCLUSIONS: Our results suggested that a trace of stool contamination remained in the perineal skin field even after the usual antiseptic skin preparation. Furthermore, meticulous skin preparation is required to minimize stool contamination in APR patients.


Assuntos
Corantes , Verde de Indocianina , Períneo/microbiologia , Períneo/cirurgia , Neoplasias Retais/cirurgia , Infecção da Ferida Cirúrgica/diagnóstico , Abdome/cirurgia , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Estudos de Viabilidade , Fezes/microbiologia , Feminino , Fluorescência , Humanos , Masculino , Radiografia , Neoplasias Retais/diagnóstico por imagem , Neoplasias Retais/patologia , Infecção da Ferida Cirúrgica/etiologia
6.
Gan To Kagaku Ryoho ; 37(1): 89-92, 2010 Jan.
Artigo em Japonês | MEDLINE | ID: mdl-20087038

RESUMO

At Nara Social Insurance Hospital, from January 2005 to September 2008, chemotherapy for older adult (>or=70) colorectal cancer patients was performed in 18 adjuvant cases and 10 advanced cases. In adjuvant cases, 18 out of 33 patients of >or= stage IIIa received chemotherapy, and 13 completed treatment safely. In advanced cases, all patients received FLOFOX or FOLFIRI, with or without bevacizumab as first-line treatment with a response rate of 50%. Although adverse events were relatively frequent in the older adult patients, there was no difference in the survival rate between elderly and younger patient groups. Cancer chemotherapy for older adults with a high comorbidity rate requires more skill and experience than for younger patients. It was possible even for a small-volume hospital, which plays an important role in regional medical service for elderly patients, to build up a system providing standard chemotherapy for colorectal cancer. However, considering the limited financial and human resources, it is essential to form a regional alliance of designated cancer care hospitals and other clinics in order to maintain the level of practice.


Assuntos
Neoplasias Colorretais/tratamento farmacológico , Idoso , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais Humanizados , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Bevacizumab , Neoplasias Colorretais/mortalidade , Fluoruracila/uso terapêutico , Humanos , Japão , Leucovorina/uso terapêutico , Compostos Organoplatínicos/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...